Cannabis Report
Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

GTBP RSS Feed
Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: 236T568, CashBowski, Duke_DD_em, cleantrader, BullsOnFire, BlissTaxi
Search This Board: 
Last Post: 5/25/2018 4:10:17 PM - Followers: 182 - Board type: Free - Posts Today: 88

OTCQB: GTBP







The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.



What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 
 

   




Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   




GT Biopharma Portfolio



GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.



Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 

 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."




 



Company Website

GTBP Investor's Overview

GTBP News



Cannabis Report
GTBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: GT BIOPHARMA ANNOUNCES UPDATE TO OXS-3550 IND FILING, ITS MOST ADVANCED TRI-SPECIFIC KILLER ENGAGER 05/16/2018 09:01:10 AM
GTBP News: Quarterly Report (10-q) 05/15/2018 06:12:45 PM
GTBP News: Current Report Filing (8-k) 05/14/2018 04:04:20 PM
GTBP News: Current Report Filing (8-k) 04/27/2018 04:03:53 PM
GTBP News: Notice of Effectiveness (effect) 03/23/2018 06:02:07 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#12944  Sticky Note GTBP (GTBP) Announces Dr. Urbanski Elevated to President cleantrader 05/14/18 09:57:42 AM
#12195  Sticky Note DUKE's MASSIVE DD POST ON $GTBP or HOW Duke_DD_em 05/04/18 08:56:30 PM
#11766  Sticky Note $GTBP Exec Team Stacked with Superstars. The Duke_DD_em 05/01/18 02:58:41 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#13949   Small green for the and of the week Level Up 05/25/18 04:10:16 PM
#13948   That will be awesome Level Up 05/25/18 03:56:08 PM
#13947   $GTBP should be releasing OXS1550 Phase 2 results StockBro75 05/25/18 03:40:52 PM
#13946   $GTBP with strong Leadership, Dr.Urbanksi (President & CMO) cryptojacko 05/25/18 03:37:51 PM
#13945   Honestly I think it’s got potential. $GTBP is cryptojacko 05/25/18 03:33:33 PM
#13944   even it's below 1.60 but it doesn't seem BearKnuckle 05/25/18 03:32:16 PM
#13943   $GTBP nice to see green in the power hour! StockBro75 05/25/18 03:30:39 PM
#13942   So much going for GTBP right now for cryptojacko 05/25/18 03:29:32 PM
#13941   Great post!!! BearKnuckle 05/25/18 03:24:05 PM
#13940   $GTBP They have been fighting to break that $1.60 BearKnuckle 05/25/18 03:23:17 PM
#13939   Power hour guys, we are back to 1.59 Level Up 05/25/18 02:57:59 PM
#13938   There is a greater potential in expansion if Level Up 05/25/18 02:10:26 PM
#13937   This is interesting..thank you Ant Level Up 05/25/18 02:09:35 PM
#13936   Looks good 1h before PH. Today can finish Level Up 05/25/18 02:09:13 PM
#13935   Green up 5,3% on $1.58 not bad Level Up 05/25/18 02:08:18 PM
#13934   True AntMiner 05/25/18 01:54:44 PM
#13933   Right now investors seem to be favoring smaller AntMiner 05/25/18 01:54:12 PM
#13932   Global Centers for Therapeutic Innovation. AntMiner 05/25/18 01:53:49 PM
#13931   $GTBP warming up pushin towards $1.70 cryptojacko 05/25/18 12:09:45 PM
#13930   Thinkin we may see 1.70 today or next week? BearKnuckle 05/25/18 12:07:20 PM
#13929   Fundamentals + Drug Pipeline + Bullish Technical = BearKnuckle 05/25/18 12:00:13 PM
#13928   I think there's a good shot for long cryptojacko 05/25/18 11:57:18 AM
#13927   $GTBP is the most undervalued gem in the BearKnuckle 05/25/18 11:50:19 AM
#13926   I think an update would give it the BearKnuckle 05/25/18 11:47:23 AM
#13925   I believe that we are in a golden BearKnuckle 05/25/18 11:45:52 AM
#13924   Yeah, I've been watching GTBP for a while BearKnuckle 05/25/18 11:45:13 AM
#13923   GT Biopharma’s pipeline of therapies have attracted several cryptojacko 05/25/18 11:40:27 AM
#13922   There's a huge reason why experienced biotech veterans cryptojacko 05/25/18 11:38:46 AM
#13921   I'm not surprise at all to read this! cryptojacko 05/25/18 10:23:45 AM
#13920   OK!! momentum building for $GTBP more buys coming BearKnuckle 05/25/18 10:22:36 AM
#13919   $GTBP Watching for the bounce on $GTBP looking cryptojacko 05/25/18 10:17:39 AM
#13918   Today looks like will be a glory day AntMiner 05/25/18 10:15:39 AM
#13917   Green Up 3.33% not bad AntMiner 05/25/18 10:14:57 AM
#13916   Nice green start Level Up 05/25/18 10:14:05 AM
#13915   Got a feeling it's finally time for the BearKnuckle 05/25/18 10:13:19 AM
#13914   It's back to green. Up 3% looking thin cryptojacko 05/25/18 10:11:36 AM
#13913   Agreed! In fact, OXS-3550 TriKE has been proven BearKnuckle 05/25/18 10:07:01 AM
#13912   $1.53 up 2% green. Great start to a BearKnuckle 05/25/18 10:03:29 AM
#13911   I think the real value in this company cryptojacko 05/25/18 10:00:56 AM
#13910   OXS-1550 uses a proprietary immunoconjugate platform technology, as BearKnuckle 05/25/18 09:59:13 AM
#13909   Based on my limited knowledge, OXS-3550 TRiKe looks BearKnuckle 05/25/18 09:58:05 AM
#13908   OXS-3550 for liquid tumors. The TRiKE platform has cryptojacko 05/25/18 09:50:53 AM
#13907   Yes, I'm aware of it that OXS-1550 uses BearKnuckle 05/25/18 09:46:07 AM
#13906   But a lot of people are talking about cryptojacko 05/25/18 09:43:42 AM
#13905   Spot on BearKnuckle! The OXS-C3550 TriKE was developed BearKnuckle 05/25/18 09:41:54 AM
#13904   Nice open making that push to the 1.60's LivH 05/25/18 09:41:24 AM
#13903   Scary data and true unfortunately but GTBP have Level Up 05/25/18 09:38:00 AM
#13902   I love that! Simple & clear right! Level Up 05/25/18 09:37:23 AM
#13901   NEW HERE? -Be sure to check out their AntMiner 05/25/18 09:36:44 AM
#13900   Early stage testing has shown great promise. Working AntMiner 05/25/18 09:36:28 AM
PostSubject